Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Newburn, Gil M.
Fraser, Allen R.
Menkes, David B.
and
Mullen, Paul E.
1990.
A Double Blind Trial of Moclobemide versus Amltrlptyllne in the Treatment of Depressive Disorders.
Australian & New Zealand Journal of Psychiatry,
Vol. 24,
Issue. 4,
p.
475.
O'Brien, Sinead
and
McKeon, Patrick
1990.
Current issues in monoamine oxidase inhibitor treatment.
Irish Journal of Psychological Medicine,
Vol. 7,
Issue. 2,
p.
159.
Schaik, Nancy van
and
Graf, Ulrich
1991.
Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster.
Mutation Research/Genetic Toxicology,
Vol. 260,
Issue. 1,
p.
99.
Chaimowitz, G.A.
Links, P.S.
Padgett, R.W.
and
Carr, A.C.
1991.
Treatment-Resistant Depression: A Survey of Practice Habits of Canadian Psychiatrists.
The Canadian Journal of Psychiatry,
Vol. 36,
Issue. 5,
p.
353.
Möller, H.-J.
and
Volz, H.-P.
1992.
Brofaromine in major depressed patients: A controlled clinical trial versus Imipramine and open follow-up of up to one year.
Journal of Affective Disorders,
Vol. 26,
Issue. 3,
p.
163.
Guelfi, J. D.
Payan, C.
Fermanian, J.
Pedarriosse, A. M.
and
Manfredi, R.
1992.
Moclobemide Versus Clomipramine in Endogenous Depression.
British Journal of Psychiatry,
Vol. 160,
Issue. 4,
p.
519.
Ramaekers, J. G.
Swijgman, H. F.
and
O'Hanlon, J. F.
1992.
Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo.
Psychopharmacology,
Vol. 106,
Issue. S1,
p.
S62.
Pinder, Roger M.
and
Wieringa, Joop H.
1993.
Third‐generation antidepressants.
Medicinal Research Reviews,
Vol. 13,
Issue. 3,
p.
259.
Möller, HJ
1993.
Therapeutic strategies in atypical depression. A German perspective.
European Psychiatry,
Vol. 8,
Issue. 5,
p.
273.
Paykel, E. S.
1995.
Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression.
Acta Psychiatrica Scandinavica,
Vol. 91,
Issue. s386,
p.
22.
Volz, H. -P.
Gleiter, C. H.
Waldmeier, P. C.
Struck, M.
and
M�ller, H. -J.
1996.
Brofaromine ? a review of its pharmacological properties and therapeutic use.
Journal of Neural Transmission,
Vol. 103,
Issue. 1-2,
p.
217.
Volz, Hans-Peter
Gleiter, Cristoph H
and
Möller, Hans-Jürgen
1997.
Brofaromine versus imipramine in in-patients with major depression – a controlled trial.
Journal of Affective Disorders,
Vol. 44,
Issue. 2-3,
p.
91.
López-Muñoz, Francisco
Álamo, Cecilio
Juckel, Georg
and
Assion, Hans-Jörg
2007.
Half a Century of Antidepressant Drugs.
Journal of Clinical Psychopharmacology,
Vol. 27,
Issue. 6,
p.
555.
Gillman, Peter Kenneth
2011.
Advances Pertaining to the Pharmacology and Interactions of Irreversible Nonselective Monoamine Oxidase Inhibitors.
Journal of Clinical Psychopharmacology,
Vol. 31,
Issue. 1,
p.
66.
López-Muñoz, Francisco
and
Álamo, Cecilio
2016.
Melatonin, Neuroprotective Agents and Antidepressant Therapy.
p.
365.
Gillman, Ken
2017.
“Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine.
CNS Spectrums,
Vol. 22,
Issue. 5,
p.
385.
eLetters
No eLetters have been published for this article.